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Abstract
Background: Mutations in the DNAI1 gene, encoding a component of outer dynein arms of the ciliary apparatus,
are the second most important genetic cause of primary ciliary dyskinesia (PCD), the genetically heterogeneous
recessive disorder with the prevalence of ~1/20,000. The estimates of the DNAI1 involvement in PCD pathogenesis
differ among the reported studies, ranging from 4% to 10%.
Methods: The coding sequence of DNAI1 was screened (SSCP analysis and direct sequencing) in a group of PCD
patients (157 families, 185 affected individuals), the first ever studied large cohort of PCD patients of Slavic origin
(mostly Polish); multiplex ligation-dependent probe amplification (MLPA) analysis was performed in a subset of ~80
families.
Results: Three previously reported mutations (IVS1+2-3insT, L513P and A538T) and two novel missense
substitutions (C388Y and G515S) were identified in 12 families (i.e. ~8% of non-related Polish PCD patients). The
structure of background SNP haplotypes indicated common origin of each of the two most frequent mutations,
IVS1+2-3insT and A538T. MLPA analysis did not reveal any significant differences between patients and control
samples. The Polish cohort was compared with all the previously studied PCD groups (a total of 487 families): IVS1
+2-3insT remained the most prevalent pathogenetic change in DNAI1 (54% of the mutations identified worldwide),
and the increased global prevalence of A538T (14%) was due to the contribution of the Polish cohort.
Conclusions: The worldwide involvement of DNAI1 mutations in PCD pathogenesis in families not preselected for
ODA defects ranges from 7 to 10%; this global estimate as well as the mutation profile differs in specific
populations. Analysis of the background SNP haplotypes suggests that the increased frequency of chromosomes
carrying A538T mutations in Polish patients may reflects local (Polish or Slavic) founder effect. Results of the MLPA
analysis indicate that no large exonic deletions are involved in PCD pathogenesis.
Background
Primary ciliary dyskinesia (PCD; MIM #242650) is a
multisystem disease characterized by recurrent respira-
tory tract infections, sinusitis, bronchiectasis and male
sub-fertility; in about half of patients it is associated
with situs inversus (Kartagener syndrome, KS; MIM
#244400), resulting from the randomization of body
symmetry (for the clarity we will refer to PCD families
without s.i. as CDO, ciliary dyskinesia only). The com-
plex PCD phenotype is caused by the impaired motility
of respiratory cilia, embryonic node cilia and sperm
tails, due to ultrastructural defects of these structures
[1]. Transmission electron microscopy detects various
structural aberrations of the axonemal ultrastructure in
over 80% of the patients [2]. The most commonly
reported defects involve absence or shortening of outer
(ODA) or inner (IDA) dynein arms-molecular motor
complexes composed of several heavy, intermediate and
light dynein chains encoded by a number of genes dis-
persed throughout the genome.
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births (1/12,500 to 1/30,000), with the prevalence of KS
being approximately two times lower [1]. PCD is usually
inherited as an autosomal recessive trait, although pedi-
grees showing autosomal dominant or X-linked modes
of inheritance have also been reported [3-6]. The com-
plexity of the ciliary ultrastructure and the broad variety
of cilia defects suggest genetic heterogeneity of the dis-
ease. Indeed, genetics of PCD is very complex, as wit-
nessed by numerous linkage studies, which indicated
several genomic regions potentially involved in PCD
pathogenesis [e.g. [7-10]]; for the reviews see [11,12].
Among several genes confirmed to be directly involved
in PCD pathogenesis, the major number of mutations
were found in just two: DNAI1 (9p13.3) and DNAH5
(5p15.2), encoding intermediate and heavy chains of the
axonemal dynein, respectively [13-21]. Mutations in other
genes, coding for proteins involved in the axonemal ultra-
structure (DNAH11, DNAI2, TXNDC3, RSPH9, RSPH4A)
or assembly (KTU, CRRC50), were reported in singular
PCD families only, and mutations in the RPGR gene were
reported in rare cases of PCD associated with the X-linked
retinitis pigmentosa (reviewed in [12]; see also [4,6,22-25].
Mutations in DNAI1 and DNAH5, both associated with
the ODA defect phenotype, were collectively estimated to
account for almost 40% (~28% and 10% for DNAH5 and
DNAI1, respectively) of PCD cases [2]. Recently, other
authors [20] reported much lower involvement of DNAI1
(4%). Here we report the results of DNAI1 screening per-
formed in a large group of predominantly Polish PCD
patients, the first large cohort of PCD patients of Slavic
origin; the possibility that large, exonic deletions account
for monoallelic mutations was also explored. Population
specificity of DNAI1 mutation spectra is discussed in light
of the SNP haplotype background of the mutations.
Materials and methods
Patients
A group of 157 PCD families included 185 affected indi-
viduals; parents and/or non-affected siblings were avail-
able in 115 families. Seventy-four of the families were
classified as KS (if at least one affected member displayed
s.i.); the remaining 83 were classified as CDO. At least
one of the criteria listed in Table 1 had to be fulfilled to
include a patient in the PCD cohort. All but six families
(Czech/Slovakian) were of Polish origin. No known par-
ental consanguinity was reported in the families (but
such a possibility was not formally excluded).
PCR amplification, SSCP/heteroduplex analysis and allele-
specific hybridization
Genomic DNA was isolated from peripheral blood lym-
phocytes using a standard salting-out extraction proce-
dure. A specific primer pair was designed for each of
the 20 DNAI1 exons, the 5’ and 3’ UTR regions, and for
five intronic SNPs; the length of each amplicon was <
300 bp. For the SSCP analysis, PCR-amplified segments
were denatured and separated in 7 or 8% polyacrylamide
(29:1) in 0.5x or 1xTBE; gels (optionally with ~2 M urea
and 10% glycerol) were run at 8-10W for 20-40 h at RT
or 4°C. Primer sequences, PCR conditions and detailed
conditions used to separate each of the analyzed frag-
ments are available from the authors upon request. The
genotyping of SNPs and of newly found mutations was
performed using dynamic ASO (allele-specific oligonu-
cleotide) hybridization [26].
Sequence analysis
The nucleotide changes underlying all the detected
SSCP migration variants were resolved by direct sequen-
cing of the PCR products (BigDyeTerminator v3.1 on an
ABI Prism 3130XL Analyzer, Applied Biosystems); trace
files were checked and edited using FinchTV1.3.1.
(Geospiza Inc.). Sequences were evaluated manually
using Chromas 1.45 software and FASTA sequence
comparison algorithm (http://fasta.bioch.virginia.edu/
fasta_www2). The reference genomic sequence was
ENSG00000122735 (http://www.ensembl.org) or
NG_008127.1 (http://www.ncbi.nlm.nih.gov); the exon
boundaries were of the 699 aminoacid DNAI1-101 tran-
script ENST00000242317 (http://www.ensembl.org); the
numbering of mutated nucleotide positions used
throughout the text is that of cDNA.
SNP-haplotype analysis and genetic stratification of the
families
Seven intragene SNPs (rs11547035, rs4879792, rs2274591,
rs3793472, rs11793196, rs9657620, rs11999046) were gen-
otyped and parental origin of the two alleles of each SNP
was determined assuming, wherever possible, no recombi-
nation among the sites. The family-based information on
SNP haplotypes was used to assess the haplotype variabil-
ity in all the patients. The consistency of the disease cose-
gregation with the haplotype variants was examined in 79
families where DNAs from proband’s siblings and parents
were available.
MLPA analysis of the DNAI1 gene
A subset of PCD patients (~80 families) were analyzed
for the potential presence of large exonic mutation(s),
using commercially available kit for multiplex ligation-
dependent probe amplification (MLPA) in the DNAI1
gene (P237-DNAI1; MRC Holland). The procedure was
performed according to the manufacturer’s indications
(MRC Holland); briefly, hybridization of the multiple
SALSA-MLPA probes (20 specific probe pairs targeting
all DNAI1 exons) to total genomic DNA sample (50 ng
per reaction) was performed at 60°C, followed by
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MLPA primers. The resulting amplicons were separated
on ABI-Prism-3130XL Analyzer; peaks were analyzed
using PeakScanner v1.0 software (Applied Biosystems).
Results
Characteristics of the detected variants
SSCP screening of the entire coding region of DNAI1
was performed in patients from 108 PCD families; sys-
tematic search for mutations was not executed in
twenty-one families where the segregation of the SNP
haplotype was inconsistent with that of the disease, as
well as in twenty-eight families where mutations were
identified in other PCD-related genes [EZ, unpublished
data]. SSCP analysis revealed eight sequence variants.
Two of them, in exon 1 and 11 (22G > T;A8 S and
1003G > A;V335I, respectively), were frequent SNPs
(rs11547035 and rs11793196), present at high frequen-
cies in the general population. The remaining six SSCP
variants represented three previously described
PCD mutations and three changes never reported before
(Figure 1). The T insertion at position +2 of intron 1
(IVS1+2-3insT), the most frequent mutation described
until now in PCD patients, is known to affect a donor
splice site [13]. It results in retaining 132 bp of intron 1
in the mRNA and the premature termination of transla-
tion at amino acid position 25. In our study, the IVS1
+2-3insT mutation was found on eleven independent
chromosomes. It was homozygous in three families,
accompanied by another mutation in three families and
was the only mutation found in two families. Another
previously reported mutation, the 1612G > A in exon 17
resulting in a missense aminoacid incorporation A538T
[18], was found on eight chromosomes; it was homozy-
gous in three families, and in two others was accompa-
nied by IVS1+2-3insT. The third of the previously
reported mutations, the 1543G > A in exon 16 (G515S)
[15], was found on one chromosome in a single patient.
The second chromosome of that patient carried a
1538T > C transition in exon 16 (L513P); that change
was never reported before. Another new mutation, the
1163G > A transition in exon 13 (C388Y), was found in
a single patient (a compound heterozygote, with IVS1
+2-3insT). The third new mutation, a G > A transition
2 4 5b pd o w n s t r e a mf r o mt h eS T O Pc o d o n ,w a sf o u n d
on one PCD chromosome; no change on the second
chromosome was identified in the patient.
Table 1 Clinical characteristic of the analyzed cohort
Criteria Number of families
Typical clinical manifestation of PCD* associated with s.i.7 4 K S
Typical clinical symptoms without s.i., AND a defect in the ciliary ultrastructure in transmission electron microscope† 32 CDO
‡
Typical clinical symptoms without s.i., and the absence of ciliary motility as seen in the light microscope 51 CD
*Recurrent upper respiratory tract infections, recurrent pneumonia, chronic bronchitis, bronchiectasis, sinusitis and otitis media, reduced mucociliary clearance as
shown by a negative result of a saccharine test;
†Usually lack of the outer/inner dynein arms, defective configuration of the microtubules;
‡TEM data were also
available for 35 KS families. In nine families (5 CDO and 4 KS), the diagnosis was supported by low values of nasal NO ( < 100 parts per billion, ppb comparedt o
normal > 600 ppb [37,38]).
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Figure 1 Characteristics of three new variants detected in PCD
patients. a. Results of the SSCP analysis revealing different
migration patterns, and pedigrees of the families where new
mutations/SNPs were identified. New mutations (in patients 537, in
his father 538, and in patients 507 and 336) are underlined. “?”
denotes unknown mutation; the carrier status is indicated by a dot
in the pedigree symbols. b. Chromatograms of the new sequence
variants.
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were available for two PCD families with the homozy-
gous mutation A538T/A538T and for two with com-
pound mutations IVS1+2-3insT/A538T. In all these
cases, the absence of ODA and/or IDA was noted; in
three of the families the absence of dynein arms was
accompanied by different, non-specific defects of micro-
tubular organization (see Table 2). Phenotype pene-
trance in the families with homozygous or compound
mutations was consistent with the recessive mode of
PCD inheritance (family members who carried only one
mutated chromosome did not exhibit any clinical
symptoms); the pedigrees of the families harboring the
newly described mutations are presented in Figure 1.
Sequence changes that resulted in a STOP or indel
mutation, or affected the two most conserved donor or
acceptor consensus splice site positions, were directly
assumed to represent causative PCD mutations. In case of
the new missense variants (L513P and C388Y), the possi-
bility that the change represented a non-pathological poly-
morphism was dismissed following a number of analyses.
Interrogation of the NCBI database for human single
nucleotide polymorphisms (build 131; http://www.ncbi.
nlm.nih.gov/SNP) indicated that no SNPs were reported at
Table 2 Details of patients’ phenotypes and PCD-associated sequence changes detected in thirteen Polish families
Family
#
Patient
#
s.i. nNO % cilia with
the defects
identified
in electron
microscope
Mutation 1 Mutation 2
Exon or
Intron
DNA Protein SVM
score
Exon or
Intron
DNA Protein SVM
score
125 480 yes na 100% ODA/IDA,
5% MT
17 1612G > A A538T -1.3 17 1612G > A A538T -1.3
106 412 yes na 38%ODA/IDA,
46% ODAorIDA,
23% MT
17 1612G > A A538T -1.3 17 1612G > A A538T -1.3
“ 413 no na na ““ “ “ ““ “ “
151 555 yes 47 80% ODA/IDA,
4% MT
17 1612G > A A538T -1.3 17 1612G > A A538T -1.3
“ 556 yes 3 100% ODA/IDA ““ “ “ ““ “ “
161 124 yes na 85% ODA/IDA,
9% MT
Intr1 IVS1+2-
3insT
S17fsX25 nr 17 1612G > A A538T -1.3
108 421 no na 87% ODA/IDA,
13% IDA
Intr1 IVS1+2-
3insT
S17fsX25 nr 17 1612G > A A538T -1.3
“ 422 no na 100% ODA/IDA,
13% IDA, 18%
MT
““ “ “ ““ “ “
124 478 yes na na Intr1 IVS1+2-
3insT
S17fsX25 nr Intr1 IVS1+2-
3insT
S17fsX25 nr
112 434 yes na na Intr1 IVS1+2-
3insT
S17fsX25 nr Intr1 IVS1+2-
3insT
S17fsX25 nr
231 520 no na na Intr1 IVS1+2-
3insT
S17fsX25 nr Intr1 IVS1+2-
3insT
S17fsX25 nr
224 507 yes na na Intr1 IVS1+2-
3insT
S17fsX25 nr 16 1538T > C L513P -2.1
238 537 yes na na 13 1163G > A C388Y -2.7 16 1543G > A G515S -2.4
244 548 no 48 na Intr1 IVS1+2-
3insT
S17fsX25 nr ? ? ? ?
216 355 no 37 na Intr1 IVS1+2-
3insT
S17fsX25 nr ? ? ? ?
“ 356 no 49 na ““ “ “ ““ “ “
“ 357 no 28 na ““ “ “ ““ “ “
145 336 yes na na 3’UTR +245G > A SNP nr ? ? ? ?
None of the reported changes were found in the control group of ~200 non-PCD chromosomes. The new +245g > a in the 3’UTR, assumed to represent SNP
rather than a pathogenetic mutation, was not included in the analysis of DNAI1 mutations prevalence. nNO-nasal NO (parts per billion); nr-not relevant; na-not
available; ? - unknown; splicing D-conserved donor splice site; MT-microtubules.
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Page 4 of 11the respective gene positions (1163G in exon 13, and
1538T in exon 16). ASO screening of the control popula-
tion (~200 unrelated chromosomes from healthy Polish
individuals) also did not reveal the mutated alleles. Com-
parison with the DNAI1 homologues from 9 Eutherian
mammals, P. troglodytes, P. pygmaeus, G. gorilla,
M. mulatta, M. musculus, R. norvegicus, B. taurus, C. fam-
ialiris, E. caballus (http://www.ensembl.org), indicated
100% conservation of DNA and aminoacid sequence at
these two positions. This is consistent with the respective
amino acids location within the DNAI1 protein: the
1163G > A substitution alters the C388 codon within the
second of five highly conserved second WD-repeats
(WD2) [13], and the 1538T > C in exon 16 changes the
S513 codon in the highly conserved inter-repeat region,
between WD3 and WD4 (Figure 2). The effect of the
amino acid changes on the protein stability was examined
using SNPs3 D online software http://www.snps3d.org; the
SVM (Support Vector Machine) value smaller than -1.0
was assumed to indicate a deleterious effect of the amino
acid substitution on the protein stability [27]. SVM scores
obtained for C388Y and L513P were -2.74 and -2.17,
respectively; of note, negative SVM scores (-2.50 and
-1.35) were also obtained for two previously reported mis-
sense mutations, G515 S and A538T. Based on all the
above observations we tentatively assumed that the newly
found missense changes in exons 13 and 16 represented
the disease-causing mutations.
The causative role of the +245G > A transition in the
3’UTR region of DNAI1 was less evident. This substitu-
tion was not found in the SNP database and in the ana-
lyzed control group, but comparison of the 3’UTR
region in ten different species indicated low conserva-
tion of the sequence position in question. The variant
was therefore analyzed in the context of sequence con-
servation in this region among different protein coding
genes. The 3’ regulatory regions are rich in regulatory
elements important for the process of mRNA 3’end
maturation. Although the sequence conservation and
length of these motifs is not very high, some common
features have been described [28]. The most important
is the highly conserved polyadenylation signal,
AAUAAA, a part of UCPAS (upstream core polyadeny-
lation signal). Downstream from it is the cutting site
(CS), where pre-mRNA is cut and the polyadenyl tail
added; it is often preceded by a CA dinucleotide. The
CS distance (10-30 bp) from two flanking segments,
UCPAS and the U/GU-rich downstream core polyade-
nylation signal (DCPAS), is the most conserved feature
of this part of the 3’ regulatory region. The G > A
Exon  16  Exon  17 
WD4 
L513P 
Human 
Gorilla 
Pan 
Macacca 
Mus 
Rattus 
Bos 
Equus 
Consensus 
>WD1  WD2 
Exon  13 
C388Y 
Human 
Gorilla 
Pan 
Macacca 
Mus 
Rattus 
Bos 
Equus 
Consensus 
Figure 2 Evolutionary conservation of the sites of two missense mutations. The positions of two missense mutations (arrows) with respect
to the position of WD-blocks 2 and 4 (boxed) in exons 13 and 16-17; species comparison indicates high evolutionary conservation.
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Page 5 of 11transition found in the patient was located 32 bp down-
stream from the first fully conserved AAUAAA
sequence after the stop codon, and within the UUGU
sequence that could be a part of the DCPAS, suggesting
its possible effect on mRNA polyadenylation (Figure 3).
However, given the generally poor conservation of the
regulatory elements among 3’UTR gene sequences,
proving the importance of this mutation cannot be
assessed without expression analyses. In addition, no
sequence change on the complementary allele was
found. The patient with the 3’UTR mutation was there-
fore not included in the analysis of DNAI mutation pre-
valence among PCD families.
MLPA analysis
Direct sequencing of the whole coding sequence (exons,
splice sites and UTRs), performed in two unrelated
patients with monoallelic mutation (IVS1+2-3insT), did
not reveal any additional sequence change. The presence
of large deletions, not detectable by SSCP and/or
sequencing, could explain the failure to detect the sec-
ond mutated allele. To examine whether this was the
case, a multiplex ligation-dependent probe amplification
(MLPA) analysis of all the DNAI1 exons was performed
in a subset of ~80 unrelated patients, including two
with the monoallelic mutation and fifteen with the
homozygous whole-length SNP-haplotype. The differ-
ences in the peaks’ height between the samples and the
control DNA from healthy individuals did not exceed
20% (not shown), indicating that no exonic deletion was
present in any of the examined patients.
Prevalence of DNAI1 mutations among Polish PCD
families
The disease-associated changes in the DNAI1 sequence
were found on 22 non-related chromosomes from
twelve families (including two with the monoallelic
mutation), which accounts for 8% of the analyzed
cohort of 157 PCD families. Interestingly, when CDO
and KS families were considered separately, the propor-
tion of those with DNAI mutations was 5% (4/83) for
CDO and 10% (8/74) for KS. Due to the small numbers,
this difference was not statistically significant (Fisher
exact test [SISA], p~0.09); however, when the propor-
tion of the affected chromosomes (rather than families)
harboring DNAI1 mutation was compared, the
difference between KS and CDO was statistically signifi-
cant (p~0.008).
The prevalence of the IVS1+2-3insT mutation among
the 22 mutated chromosomes was 50%, and that of
A538T was 36%. To examine the possibility of founder
effect(s) being responsible for their distribution in Polish
population, DNAI1 mutations were analyzed in context
of SNP haplotype background.
SNP haplotype background
Variants of the 7-position SNP haplotype (flanked by
markers located in exon 1 and intron 18 of the DNAI1
gene) were determined in 142 families, including 32 for
which linkage of the disease phenotype with DNAI1 was
excluded (all chromosomes from these 32 families were
considered non-affected). Among the 142 families, 56
had both parents and one (15 families) or more
(41 families) children genotyped, in 22 no genotype data
was available for one or both parents, and in 64 only a
singleton patient was genotyped. Converting the geno-
type data into haplotypes was aided by the fact that in
almost half families (66 families, including 41 singleton
patients) at least one of the members was homozygous
or heterozygous only at a single SNP position, i.e., hap-
lotype phase could be solved directly. Of the 142, 78
families were informative with respect to the parental
contribution of the chromosomes. In the remaining
families and in the multiply heterozygous singleton
patients, determination of the alleles’ phase from
genotype data was based on the maximum parsimony
principle, taking into account the frequency of the
unambiguously determined haplotypes and assuming no
recombination whenever possible. In three of the
families, the unambiguous solution couldn’t be achieved
and these were excluded from further haplotype
analysis.
The resulting distribution of the haplotypes among
395 non-related chromosomes (183 non-affected and
212 affected) is given in Figure 4. Sixteen haplotype var-
iants were distinguished. Their frequency did not differ
significantly when the affected and non-affected chro-
mosomes were compared. Eight of the haplotypes
occurred at relatively high frequencies (4-21%) in the
whole analyzed group of 395 chromosomes; the allelic
s t r u c t u r eo fn i n er a r eh a p l o t y p e s( f r e q u e n c y≤ 1%) sug-
gested that they represented recent recombinants of the
frequent variants. Only one of these recombination
...TGA(200bp)TGCACAAAUAAACCUGUGUAGAAACCCACCCCACACCUUUAAUU(G>A)UGCUACCACAGGGCCCU...
Stop 
codon               
polyA signal 
(a part of UCPAS)  
CA preceding  
cutting site                    
UUGU 
(a part of DCPAS) 
Figure 3 Substitution in the DNAI1 3’UTR region. The position of the substitution is highlighted; putative regulatory motifs in the DNAI1
3’UTR region are underlined.
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remaining eight recombinants must have already “circu-
lated” in the population.
The most prevalent IVS1+2-3insT mutation (found on
eleven independent Polish chromosomes), was always
found on the G-g-g-t-G-g-c haplotype (lower-case let-
ters indicate SNPs in introns). This common back-
ground is consistent with the mutation’si d e n t i t yb y
descent (i.b.d.) in all the analyzed chromosomes.
Another recurring mutation, A538T, was associated
with the G-g-g-t-G-g-g haplotype on seven of the eight
independent chromosomes, again indicating their recent
common origin. Two chromosomes carrying unidenti-
fied mutations (in two unrelated patients with the
monoallelic IVS1+2-3insT) had an identical haplotype
G-g-g-t-A-a-g
a (g
a at the last position of the haplotype
denotes ancestral “g” at rs11999046 linked with the
derived “a” 93 nt downstream from rs11999046). The
identity of the haplotypes background suggests that both
families may share the same unidentified complementary
mutation.
On the other hand, the background haplotypes for
IVS1+2-3insT, A538T and the unknown mutation(s) are
relatively frequent also among the non-affected chromo-
somes (10.9%, 5.5% and 4.9%, respectively). Therefore,
the possibility that recurrent mutation events rather
than i.b.d. are responsible for the relatively high fre-
quency of these mutations cannot be excluded. In this
context it has to be noted that the 1612G > A mutation
on one of the eight chromosomes was associated with a
different haplotype, G-g-g-c-G-g-g. The structure of the
G-g-g-c-G-g-g cannot be explained by a single recombi-
nation event between two frequent haplotypes (Figure
4), and possible explanations include: 1) a double
recombination or a gene conversion involving the fre-
quent haplotype carrying the founder mutation (or its
recombination with a very rare variant); 2) the possibi-
lity that the less common haplotype is derived from the
common haplotype by a mutation at rs3793472; or 3) an
independent mutation, which had occurred on a rare
haplotype background. The first scenario would suggest
the older age of the mutation, since the probability of a
recombination or conversion event increases with time
(e.g. [29]). Assuming the genomic average of 44 recom-
binations per meiosis per generation [30], the average
genomic crossover rate is 10
-8 per bp per generation,
SNP or 
mutation 
SNP1  Splice  SNP2  SNP3  SNP4  SNP5  C388Y  SNP6 
L513P 
G515S  A538T  SNP7 
 
Number of chromosomes 
Location  Ex.1  Int.1  Int.1  Int.4  Int.8  Ex.11  Ex.13  Int.15  Ex.16  Ex.17  Int.18   
Non-
affected 
Affected 
Ancestral  G  Wild   g  g  t  G  Wild   a  Wild   Wild   g    No 
mutation 
With 
mutation  Derived  T  Mut.  c  a  c  A
*  Mut.  g  Mut.  Mut.
*  c   
                               
H1  0  0  0  0  0  0  0  1  0  1612G>A  0    10  7  7
† 
H1r  0  0  0  0  0  0  0  0  0  0  0    2  0    
H2  0  +2-3insT  0  0  0  0  0  1  0  0  1    20  19  11 
H3  1  0  0  0  0  0  0  0  0  0  0    10  14    
H4  0  0  0  1  0  0  0  0  0  0  0    20  24    
H4r  0  0  0  1  0  0  0  1  0  0  0    0  2    
H5  0  0  0  0  0  1  0  0  0  0  1    30  25    
H5r1  0  0  0  0  0  1  0  0  0  0  0    1  3    
H5r2
‡  0  0  1  0  1  1  0  0  0  0  1    1  0    
H5r1r3  0  0  1  0  0  1  0  0  0  0  0    1  0    
H6  0  0  0  0  0  1  0  0  0  0  0-1
§    9  6  2
** 
H7  0  0  1  0  0  0  1163G>A  1  1538T>C  0  0    36  46  1+1 
H7r  0  0  1  0  0  0  0  1  0  0  1    1  0    
H8  0  0  1  0  1  0  0  1  1543G>A  0  0    37  40  1 
H8r1  0  0  1  0  1  0  0  1  0  0  1    2  2    
H8r2  0  0  0  0  1  0  0  1  0  1612G>A  0    3  0  1
† 
 
Figure 4 Distribution of the 7-position SNP haplotype variants among the studied chromosomes. Positions of the pathogenic mutations
are indicated in on the SNP haplotype background. H1 through H8r2 are arbitrary names of the variants of the 7-position SNP haplotype. SNP1,
2, 3, 4, 5, 6 and 7 denote, respectively, rs11547035, rs4879792, rs2274591, rs3793472, rs11793196, rs9657620, rs11999046. Letters “0” and “1” in the
left section of this Figure indicate, respectively, the ancestral and derived allele of the SNPs (the ancestral alleles were determined from the
human-chimpanzee comparison, with the sequence identity indicating the ancestral state). Minimal regions of recombination (letter “r” in the
haplotype name) in the rare haplotype variants, proposed assuming most parsimonious recombination among the frequent variants, and taking
into account the extent of LD in the gene region (Figure 5), are highlighted. Right section of the Figure indicates the number of chromosomes
with the respective haplotype variants. *G > A at rs11793196 and c.1612 are transitions at CpG dinucleotides.
†Mutation A538T on the H1
background was found only in KS families; A538T on the H8r2 was found in a CDO family.
‡Recombination detected within the PCD family.
§ “0-
1” at the last position of the H6 haplotype denotes ancestral allele (G) at rs11999046, linked with the derived allele (A) 93 nt downstream from
rs11999046. **Unknown mutation(s) in two PCD families.
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Page 7 of 11and 6x10
-5 per 6 kb of the DNAI1 haplotype. One could
therefore expect a single recombination event to occur
once in 10
4 generations or once in ~200,000 years, and
the probability of double recombination event is even
lower. Moreover, the DNAI region flanked by markers
rs11547036 (in exon 1) and rs11793196 (in exon 11),
where at least one of the purported recombination events
would have to take place, is characterized by the high level
of linkage disequilibrium (Figure 5) in the HapMapCEU
sample (http://hapmap.ncbi.nlm.nih.gov; [31,32]). The sec-
ond scenario, of the recurrent mutation at rs3793472,
would point to the identity of 1612G > A mutation in
both haplotypes (G-g-g-t-G-g-g and G-g-g-c-G-g-g). How-
ever, since identical background haplotypes were also
found on the unrelated healthy chromosomes (Figure 4),
the t > c substitution at rs3793472 would have had to
occur independently on the chromosomes with and with-
out A538T mutation. With the average mutation rate of
1-4x10
-8 per bp per generation [33,34], this is not highly
probable. Regarding the fact that the 1612G > A transition
leading to A538T occurred within a CpG dinucleotide,
known to mutate 10 times faster than other sequence
positions [35], the third scenario, of an independent recur-
rent origin of this mutation, appears therefore most
plausible.
Discussion
Prevalence of DNAI1 mutations among PCD families of
various ethnicities
The disease-associated DNAI mutations were found in
8% of the analyzed Polish PCD families (12/157). This
estimate is consistent with the previously reported DNAI
involvement in 9% of PCD families (16/179) [18]; the ear-
lier, even higher, reported values were based on much
smaller study groups [13,16]. On the other hand, DNAI1
mutations were found in only 4% of the 104 PCD families
analyzed in another study [20]. The authors suggested
that the previously reported involvement of DNAI1
mutations reflected bias in the recruitment of PCD
patients through detection of ODA defects. Indeed, the
frequency of DNAI1 mutations in the pre-selected PCD
subpopulation with documented ODA defects has been
shown to be higher (14%) [2,18]. However, our estimate
of 8% is based on the total number of Polish families,
recruited without any preselection. Similarly, the criti-
cized estimate of 9% [18] has been calculated with
respect to all the 179 PCD families recruited for that
study; even if the proportion of families with ODA
d e f e c t si nt h a tc o h o r tw a ss h o w nt ob e~ 8 0 % ,i td i dn o t
necessarily reflect biased recruitment but rather the fre-
quent presence of ODA defects among PCD patients in
general. Therefore, the lowest reported involvement of
DNAI1 [20] may reflect other factors, for example ethnic
differences in the analyzed cohorts.
Of the 104 families analyzed by Failly et al. [20], 101
were Caucasian, with the predominant (3/4) contribu-
tion of Swiss (n = 50) or Italian (n = 32). The cohort
analyzed by Zariwala et al. [18] was ethnically more het-
erogeneous: 155 of 179 families were Caucasian, and
among 90 families for whom the ethnicity data were
provided, the majority were German (n = 28), French
(n =2 3 ) ,U K( n = 18) and Australian (n =1 1 ) ;o n l y6
samples were Italian, and no Swiss samples were
reported. Our study group (n = 157) was predominantly
Polish (n = 151); six families of Chech/Slovakian origin
belong to the populations which are geographically and
ethnically very close to Poles (all belong to West Slavs).
Our results indicate that Poles (West Slavs), do not
significantly differ from German, French or British
populations when the DNAI1 involvement in PCD
pathogenesis is considered [13,16,18]. The low preva-
lence of DNAI1 mutations among patients of Italian and
Swiss origin [20] may either reflect specificity of these
two populations or result from a clinal distribution of
DNAI1 mutations, with the frequency gradient running
in South-North rather than West-East direction. The
existence of such gradients in Europe can be exemplified
by the frequency distribution of the F508del mutation in
the CFTR gene [36]. Answering the question whether
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Figure 5 Linkage disequilibrium (LD) across the DNAI1 gene.
Based on the HapMapCEU SNPs triangle plot generated for HapMap
CEU data (release 21) for ENSG00000122735 (chrom 9:34457-34521
kb) with the use of Haploview software. Positions of SNPs
genotyped in PCD families are indicated by arrowheads (rs11547035
and rs4879792, blue arrowheads, are not among SNPs from the
HapMapCEU panel). The strength of the LD between SNPs (solid
spine of LD) is indicated by colors: white (low) and dark (high); LD
blocks are indicated by black triangles. Haplotypes flanked by
markers rs11547036 and rs11793196 are within a single block of LD.
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Page 8 of 11the differences in DNAI1 involvement is due to the pos-
sible European clines in the geographical distribution of
mutations or to the local founder effects will require
studying PCD patients from other European
populations.
Population spectrum of DNAI1 mutations
The spectrum of DNAI1 mutations detected up to date in
all the relevant studies is shown in Table 3. The preva-
lence of IVS1+2-3insT among the Polish PCD chromo-
somes harboring DNAI1 mutations (50%, 11/22) is only
slightly lower than the respective value based on all the
previous reports (56%, 27/48) [13,15,18,20]. The common
background of this mutation in all the Polish chromo-
somes is consistent with their identity by descent. The
origin of the recurring IVS1+2-3insT from the common
founder has been suggested in earlier studies based on
sharing allele 19CA of the nearby microsatellite
D9S1805, located 0.26 Mb upstream of DNAI1 [18].
The relatively high prevalence of A538T (36%, 8/22)
appears to be specific for the Polish population; in all
the other studies combined, this mutation represented
only 1% (2/48) of DNAI mutations. Polish cohort is the
only population where PCD patients homozygous for
other alleles than IVS1+2-3T were found: three families
without reported consanguinity were homozygous for
A538T. The high frequency of A583T among Polish
patients most likely reflects two phenomena: the com-
mon origin (founder mutation) in most families, and an
independent mutation event on a different haplotype
background in another family. Further studies involving
other Eastern-European PCD cohort/s would be
Table 3 The distribution of mutations reported up to date in the KS and CDO families
Study Pennarun99 Guichard01 Zariwala01 Zariwala06 Failly08 This
study
All
KS CDO KS CDO KS CDO KS CDO KS CDO KS CDO KS CDO
Families (n = 487)
Cohort size (# families) 2 4 34 - 5 2 93 86 61 43 74 83 269 218
Families with mutations
detected
(% of all studied PCD families)
2 mutations 13 1177 1 1 8 221
(8%)
17
(8%)
1 mutation 11 2 2
Exon/Intron Mutation Effect Chromosomes with mutations (n = 70)
In1 IVS1+2-3insT S17fsX25 1 3 1 1 10 7 2 2 6 5 22 16
Ex5 282-283 insAATA G95N fsX24 1 1
Ex6 463delA T155LfsX18 1 1
Ex7 520G > A E174L 1 1
In7 IVS7-2A > G splicingAcc 1 1
Ex10 874C > T Q292X 1 1
In10 IVS10-4-7 delGTTT splicingAcc 1 1
Ex13 1163G > A C388Y 1 1
“ 1212T > G Y404X 1 1
“ 1222G > A V408M 1 1
“ 1307G > A W436X 1 1
Ex16 1490G > A R468-K523del 1 1
“ 1538T > C L513P 1 1
“ 1543G > A G515S 2 1 3
Ex17 1612G > A A538T 1 1 7 1 82
“ 1644G > A W548X 1 1
“ 1657-68del T553-F556del 1 1
“ 1703G > C W568S 1 1 11
“ 1704G > A W568X 1 1
Ex19 1926-7insCC I643PfsX48 1 1
In19 IVS19+1G > A A607-K667del 1 1
Number of chromosomes with DNAI1 mutations (% of all PCD chromosomes) 41 (8%) 29 (7%)
Based on the data from [[13,15,16,18,20] this study].
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Page 9 of 11required to elucidate whether the founder mutation is
restricted to the Polish population or characteristic for
other Slavic groups. The excess of Polish PCD chromo-
somes harboring A538T was observed among the KS
families; in fact, it is this mutation, which mostly con-
tributed to the DNAI1 involvement being higher in KS
than in CDO families.
Importantly for diagnostic purposes, A538T is located
in exon 17, and two new mutations detected in this
study (C388Y and L513P)-in exons 13 and 16, respec-
tively, such that most of the mutant alleles remain clus-
tered in intron 1 and exons 13, 16 and 17, as previously
reported [2,18]. Chromosomes harboring mutations in
these regions make up 80% of all the PCD chromosomes
with the reported DNAI1 involvement. Of note, while
the rare nonsense mutations or changes introducing a
f r a m es h i f ta r ed i s t r i b u t e da l o n gt h ew h o l ec o d i n g
sequence, all but one (E174L) missense mutations are
found in exons 13, 16 and 17.
A question of unidentified DNAI1 mutations
Among a total of 38 PCD families with the DNAI muta-
tions found in different studies, six were “monoallelic”,
with only one mutation identified in spite of direct
sequencing of the whole coding region [[18,20] this
study]. In four of these families, the single mutation
found was the frequent IVS1+2-3insT. Is it possible that
the affected members in these four families were just
carriers of the detected mutation (with DNAI1 not being
involved in PCD pathogenesis)? In such a case, the esti-
mate of DNAI1 involvement in PCD pathogenesis would
be slightly lower (7%; 34/487). With the disease preva-
lence of 1/20,000, DNAI1 involvement of ~7-10%, and
IVS1+2-3insT prevalence among DNAI1 mutations of
~50%, the chance of picking up an asymptomatic IVS1
+2-3insT carrier in the general population is ~1/535-1/
450. Given that 487 independent PCD families were
analyzed in all the reported studies, one would expect at
most one of the patients to be an asymptomatic carrier
of IVS1+2-3insT; the observed number of four carriers
is higher, although the difference does not reach the
level of statistical significance (p = 0.15; Fisher test).
Nevertheless, we tentatively assume that DNAI1 is actu-
ally involved in PCD pathogenesis in the families with
monoallelic mutation. In that case, the second mutation
must have been undetectable by SSCP screening and
direct sequencing of the amplified exonic segments. One
of the possible explanations- the presence of long exonic
deletion - was excluded, since the MLPA analysis using
probes targeting all the DNAI1 exons did not reveal any
differences in the amplification intensity of the PCD
patients as compared to healthy controls. However, deep
intronic or extragenic regulatory mutations remain to be
searched for. Finally, the possibility that the inheritance
of PCD in some families is di- or trigenic cannot be for-
mally excluded, but so far no evidence exists which
could substantiate this hypothesis.
Conclusions
The analysis of the Polish PCD patients confirms large
genetic heterogeneity of the disease and indicates that
the worldwide involvement of DNAI1 mutations in PCD
pathogenesis ranges from 7 to 10% in the families not
preselected for the ODA defects; however, the involve-
ment in specific populations may differ from this global
estimate. In the combined PCD cohorts from all up to
date studies, the IVS1+2-3insT remains the most preva-
lent pathogenetic change in DNAI1 (54% of all the
mutations identified worldwide). The increased global
prevalence of A538T (14%) is due to the contribution of
the Polish cohort, in which the high frequency of this
mutation (36%) probably reflects the local (Polish or
Slavic) founder effect. The spectrum of mutations
detected in the Polish cohort confirms earlier observa-
tions of mutations clustering in (or around) exons 1, 13,
16 and 17 of the DNAI1 gene, indicating directions for
future diagnostic tests. Finally, with MLPA results indi-
cating that no large exonic DNAI1 deletions are involved
in PCD pathogenesis, the question of undetected muta-
tions still remains open.
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